Tags : Lundbecks

Biotech Regulatory

Lundbeck’s Vyepti (eptinezumab-jjmr) Receives the US FDA’s Approval to Prevent

Shots: The approval is based on two P-IIItrials PROMISE-1 in episodic migraine and PROMISE-2 in chronic migraine  involves assessing of Vyepti (100mg or 300mg) vsPBO in 2076 patients with migraine PROMISE 1 study results: mean migraine frequency ~8.6 migraine days/month, mean change in MMD in 1-3mos. @100mg or 300mg  (-3.9 days, -4.3 days vs -3.2 […]Read More